GRCE
Financials
- Market Capitalization 40.03 M
- Employee 5
- Founded 2002
- CEO N/A
- Website www.gracetx.com
- Headquarter Delaware, United States
- FIGI BBG001NMDXS6
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 4388 |  PDSB PDS Biotechnology Corporation - Common Stock | 0.72 USD | -4.00% | -11.11% | -33.33% | -40.98% | 40.19 M USD | ||
| 4394 |  LTRN Lantern Pharma Inc. - Common Stock | 3.27 USD | -5.49% | -8.40% | -18.45% | -21.96% | 36.97 M USD | ||
| 4403 |  VERU Veru Inc. - Common Stock | 2.35 USD | -8.20% | -17.25% | -22.19% | -1.67% | 37.72 M USD | ||
| 4408 |  DYAI Dyadic International, Inc. - Common Stock | 1.05 USD | +2.94% | -1.87% | +47.89% | +5.00% | 38.26 M USD |
Frequently asked questions about Grace Therapeutics, Inc. - Common Stock
What is the Grace Therapeutics, Inc. - Common Stock stock price today?
The current price of Grace Therapeutics, Inc. - Common Stock (GRCE) is 2.46. Over the past 24 hours, the stock has changed by +1.23%. Follow the GRCE chart for real-time price dynamics.
What is the stock ticker of Grace Therapeutics, Inc. - Common Stock?
Grace Therapeutics, Inc. - Common Stock trades under the ticker GRCE. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Grace Therapeutics, Inc. - Common Stock stock going up?
GRCE has changed by -0.40% over the last week, +11.82% over the last month, and -38.19% over the last year. Review the chart to see whether the current move is part of a broader trend.
What was Grace Therapeutics, Inc. - Common Stock net income for the last quarter?
Grace Therapeutics, Inc. - Common Stock reported net income of -1.18 M for the last quarter. The previous quarter showed -2.31 M, which means net income changed by +49.11%.
How many employees does Grace Therapeutics, Inc. - Common Stock have?
As of the latest available data, Grace Therapeutics, Inc. - Common Stock has 5 employees. Workforce size can provide additional context about the company's scale and operations.
What is Grace Therapeutics, Inc. - Common Stock EBITDA?
Grace Therapeutics, Inc. - Common Stock EBITDA is -2.59 M, and its EBITDA margin is 37.06 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Grace Therapeutics, Inc. - Common Stock stock?
You can buy Grace Therapeutics, Inc. - Common Stock (GRCE) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Grace Therapeutics, Inc. - Common Stock stock?
Investing in Grace Therapeutics, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the GRCE chart and related analysis on metatrader.com as part of your research.